Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 717919, 9 pages
http://dx.doi.org/10.1155/2014/717919
Review Article

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma

1Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077
2Cancer Science Institute of Singapore, National University of Singapore, Singapore 117599

Received 17 March 2014; Accepted 20 May 2014; Published 17 June 2014

Academic Editor: Dong Soon Lee

Copyright © 2014 P. J. Teoh and W. J. Chng. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. H. Vousden and X. Lu, “Live or let die: the cell's response to p53,” Nature Reviews Cancer, vol. 2, no. 8, pp. 594–604, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Volgelstein, D. Lane, and A. J. Levine, “Surfing the p53 network,” Nature, vol. 408, pp. 307–310, 2000. View at Publisher · View at Google Scholar
  3. D. Malkin, F. P. Li, L. C. Strong et al., “Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms,” Science, vol. 250, no. 4985, pp. 1233–1238, 1990. View at Google Scholar · View at Scopus
  4. A. M. Goh, C. R. Coffill, and D. P. Lane, “The role of mutant p53 in human cancer,” Journal of Pathology, vol. 223, no. 2, pp. 116–126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. P. A. J. Muller and K. H. Vousden, “P53 mutations in cancer,” Nature Cell Biology, vol. 15, no. 1, pp. 2–8, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. W. J. Chng, T. Price-Troska, N. Gonzalez-Paz et al., “Clinical significance of TP53 mutation in myeloma,” Leukemia, vol. 21, no. 3, pp. 582–584, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Lodé, M. Eveillard, V. Trichet et al., “Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma,” Haematologica, vol. 95, no. 11, pp. 1973–1976, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Drach, J. Ackermann, E. Fritz et al., “Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy,” Blood, vol. 92, no. 3, pp. 802–809, 1998. View at Google Scholar · View at Scopus
  9. K. D. Boyd, F. M. Ross, W. J. Tapper et al., “The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy,” Genes Chromosomes and Cancer, vol. 50, no. 10, pp. 765–774, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Fonseca, E. Blood, M. Rue et al., “Clinical and biologic implications of recurrent genomic aberrations in myeloma,” Blood, vol. 101, no. 11, pp. 4569–4575, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. M. H. Chen, C. X. Y. Qi, M. N. Saha, and H. Chang, “p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide,” American Journal of Clinical Pathology, vol. 137, no. 2, pp. 208–212, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Chang, C. Qi, Q. L. Yi, D. Reece, and A. K. Stewart, “p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation,” Blood, vol. 105, no. 1, pp. 358–360, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Xiong, X. Wu, S. Starnes et al., “An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma,” Blood, vol. 112, no. 10, pp. 4235–4246, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Chou, “Multiple myeloma: recent progress in diagnosis and treatment,” Journal of Clinical and Experimental Hematopathology, vol. 52, no. 3, pp. 149–159, 2012. View at Google Scholar · View at Scopus
  15. M. O. Elnenaei, A. M. Gruszka-Westwood, R. A'Hern et al., “Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A,” Haematologica, vol. 88, no. 5, pp. 529–537, 2003. View at Google Scholar · View at Scopus
  16. H. Chang, S. Sloan, D. Li, and A. K. Stewart, “Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions,” British Journal of Haematology, vol. 127, no. 3, pp. 280–284, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Billecke, E. M. M. Penas, A. M. May et al., “Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma,” Anticancer Research, vol. 32, no. 5, pp. 2031–2034, 2012. View at Google Scholar · View at Scopus
  18. S. Mangiacavalli, L. Pochintesta, F. Cocito et al., “Correlation between burden of 17p13.1 alteration and rapid escape to plasma cell leukaemia in multiple myeloma,” British Journal of Haematology, vol. 162, no. 4, pp. 555–558, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Vicente-Dueñas, I. González-Herrero, M. B. G. Cenador, F. J. G. Criado, and I. Sánchez-García, “Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells byMafB,” Cell Cycle, vol. 11, no. 20, pp. 3896–3900, 2012. View at Publisher · View at Google Scholar
  20. J. Chung and M. S. Irwin, “Targeting the p53-family in cancer and chemosensitivity: triple threat,” Current Drug Targets, vol. 11, no. 6, pp. 667–681, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Allende-Vega and M. K. Saville, “Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy,” Seminars in Cancer Biology, vol. 20, no. 1, pp. 29–39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Haupt, M. Berger, Z. Goldberg, and Y. Haupt, “Apoptosis—the p53 network,” Journal of Cell Science, vol. 116, no. 20, pp. 4077–4085, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. U. M. Moll and O. Petrenko, “The MDM2-p53 Interaction,” Molecular Cancer Research, vol. 1, no. 14, pp. 1001–1008, 2003. View at Google Scholar · View at Scopus
  24. M. Wade, Y. C. Li, and G. M. Wahl, “MDM2, MDMX and p53 in oncogenesis and cancer therapy,” Nature Reviews Cancer, vol. 13, no. 2, pp. 83–96, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Toledo and G. M. Wahl, “Regulating the p53 pathway: in vitro hypotheses, in vivo veritas,” Nature Reviews Cancer, vol. 6, no. 12, pp. 909–923, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Quesnel, C. Preudhomme, D. Oscier et al., “Over-expression of the MDM2 gene is found in some cases of haematological malignancies,” British Journal of Haematology, vol. 88, no. 2, pp. 415–418, 1994. View at Google Scholar · View at Scopus
  27. G. Teoh, M. Urashima, A. Ogata et al., “MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells,” Blood, vol. 90, no. 5, pp. 1982–1992, 1997. View at Google Scholar · View at Scopus
  28. W. J. Chng, O. Glebov, P. L. Bergsagel, and W. M. Kuehl, “Genetic events in the pathogenesis of multiple myeloma,” Best Practice and Research: Clinical Haematology, vol. 20, no. 4, pp. 571–596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Hanamura, J. P. Stewart, Y. Huang et al., “Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation,” Blood, vol. 108, no. 5, pp. 1724–1732, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Pichiorri, S. S. Suh, M. Ladetto et al., “MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 35, pp. 12885–12890, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Pichiorri, L. de Luca, and R. I. Aqeilan, “MicroRNAs: new players in multiple myeloma,” Frontiers in Genetics, vol. 2, article 22, 2011. View at Publisher · View at Google Scholar
  32. W. Hu, C. S. Chan, R. Wu et al., “Negative regulation of tumor suppressor p53 by microRNA miR-504,” Molecular Cell, vol. 38, no. 5, pp. 689–699, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. T. N. Le, C. Teh., N. Shyh-Chang et al., “MicroRNA-125b is a novel negative regulator of p53,” Genes and Development, vol. 23, no. 7, pp. 862–876, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Kumar, Z. Lu, A. A. L. Takwi et al., “Negative regulation of the tumor suppressor p53 gene by microRNAs,” Oncogene, vol. 30, no. 7, pp. 843–853, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Amir, A. H. Ma, X. B. Shi, L. Xue, H. J. Kung, and R. W. deVere White, “Oncomir miR-125b suppresses p14ARF to modulate p53-dependent and p53-independent apoptosis in prostate cancer,” PLoS ONE, vol. 8, no. 4, Article ID e61064, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. N. E. Sharpless, “INK4a/ARF: a multifunctional tumor suppressor locus,” Mutation Research: Fundamental and Molecular Mechanisms of Mutagenesis, vol. 576, no. 1-2, pp. 22–38, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. W. Lu, Y. Xie, Y. Ma, R. J. Matusik, and Z. Chen, “ARF represses androgen receptor transactivation in prostate cancer,” Molecular Endocrinology, vol. 27, no. 4, pp. 635–648, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Stanganelli, J. Arbelbide, D. B. Fantl, C. Corrado, and I. Slavutsky, “DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance,” Annals of Hematology, vol. 89, no. 2, pp. 191–199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. D. R. Hodge, B. Peng, J. C. Cherry et al., “Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation,” Cancer Research, vol. 65, no. 11, pp. 4673–4682, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. E. M. Hurt, S. B. Thomas, B. Peng, and W. L. Farrar, “Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator,” Cancer Biology and Therapy, vol. 5, no. 9, pp. 1154–1160, 2006. View at Google Scholar · View at Scopus
  41. D. P. Lane, C. F. Cheok, and S. Lain, “p53-based cancer therapy,” Cold Spring Harbor Perspectives in Biology, vol. 2, no. 9, Article ID a001222, 2010. View at Google Scholar · View at Scopus
  42. Q. Liu and Y. Gazitt, “Adenovirus-mediated delivery of p53 results in substantial apoptosis to myeloma cells and is not cytotoxic to flow-sorted CD34+ hematopoietic progenitor cells and normal lymphocytes,” Experimental Hematology, vol. 28, no. 12, pp. 1354–1362, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. D. Tan, W. J. Chng, T. Chou et al., “Management of multiple myeloma in Asia: resource-stratified guidelines,” The Lancet Oncology, vol. 14, no. 12, pp. 70404–70402, 2013. View at Publisher · View at Google Scholar
  44. R. Castelli, R. Gualtierotti, N. Orofino, A. Losurdo, S. Gandolfi, and M. Cugno, “Current and emerging treatment options for patients with relapsed myeloma,” Clinical Medicine Insights: Oncology, vol. 7, pp. 209–219, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Monneret, J. P. Buisson, and H. Magdelenat, “A new therapy with bortezomib, an oncologic medicinal product of the year 2004,” Annales Pharmaceutiques Francaises, vol. 63, no. 5, pp. 343–349, 2005. View at Google Scholar · View at Scopus
  46. C. M. Eischen and G. Lozano, “The Mdm network and its regulation of p53 activities: a rheostat of cancer risk,” Human Mutation, vol. 35, no. 6, pp. 728–737, 2014. View at Publisher · View at Google Scholar
  47. F. Toledo and G. M. Wahl, “MDM2 and MDM4: p53 regulators as targets in anticancer therapy,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 7-8, pp. 1476–1482, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Matta and P. M. Chaudhary, “The proteasome inhibitor Bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells,” Cancer Biology and Therapy, vol. 4, no. 1, pp. 77–82, 2005. View at Google Scholar · View at Scopus
  49. Y. H. Ling, L. Liebes, J. D. Jiang et al., “Mechanisms of proteasome inhibitor PS-341-induced G2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines,” Clinical Cancer Research, vol. 9, no. 3, pp. 1145–1154, 2003. View at Google Scholar · View at Scopus
  50. Y. H. Ling, L. Liebes, B. Ng et al., “PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis,” Molecular Cancer Therapeutics, vol. 1, no. 10, pp. 841–849, 2002. View at Google Scholar · View at Scopus
  51. P. G. Richardson, B. Barlogie, J. Berenson et al., “A phase 2 study of Bortezomib in relapsed, refractory myeloma,” New England Journal of Medicine, vol. 348, no. 26, pp. 2609–2617, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Jagannath, B. Barlogie, J. Berenson et al., “A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma,” British Journal of Haematology, vol. 127, no. 2, pp. 165–172, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. S. K. Kumar, S. V. Rajkumar, A. Dispenzieri et al., “Improved survival in multiple myeloma and the impact of novel therapies,” Blood, vol. 111, no. 5, pp. 2516–2520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. J. B. Berenson, S. Jagannath, B. Barlogie et al., “Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma,” Cancer, vol. 104, no. 10, pp. 2141–2148, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. M. N. Saha, J. Micallef, L. Qiu, and H. Chang, “Pharmacological activation of the p53 pathway in haematological malignancies,” Journal of Clinical Pathology, vol. 63, no. 3, pp. 204–209, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. L. T. Vassilev, B. T. Vu, B. Graves et al., “In vivo activation of the p53 pathway by small-molecule antagonists of MDM2,” Science, vol. 303, no. 5659, pp. 844–848, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. M. N. Saha, L. Qiu, and H. Chang, “Targeting p53 by small molecules in hematological malignancies,” Journal of Hematology and Oncology, vol. 6, no. 1, article 23, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Stühmer, M. Chatterjee, M. Hildebrandt et al., “Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma,” Blood, vol. 106, no. 10, pp. 3609–3617, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. M. N. Saha, H. Jiang, and H. Chang, “Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways,” Cancer Biology and Therapy, vol. 10, no. 6, pp. 567–578, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. M. N. Saha, J. Jayakar, and H. Chang, “Nutlin-3 and velcade synergistically induce cell cycle arrest and apoptosis in multiple myeloma through activation of p53 pathway,” Modern Pathology, vol. 22, no. 1s, article 1287, 2009. View at Publisher · View at Google Scholar
  61. M. N. Saha, H. Jiang, J. Jayakar, D. Reece, D. R. Branch, and H. Chang, “MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity,” Cancer Biology and Therapy, vol. 9, no. 11, pp. 937–945, 2010. View at Google Scholar · View at Scopus
  62. P. J. Teoh, T. H. Chung, S. Sebastian et al., “p53 haploinsufficiency and functional abnormalities in multiple myeloma,” Leukemia, vol. 14, article 102, no. 10, 2014. View at Publisher · View at Google Scholar
  63. M. H. Aziz, H. Shen, and C. G. Maki, “Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3,” Oncogene, vol. 30, no. 46, pp. 4678–4686, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. J. T. Patton, L. D. Mayo, A. D. Singhi, A. V. Gudkov, G. R. Stark, and M. W. Jackson, “Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3,” Cancer Research, vol. 66, no. 6, pp. 3169–3176, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. M. N. Saha, H. Jiang, A. Mukai, and H. Chang, “RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses,” Molecular Cancer Therapeutics, vol. 9, no. 11, pp. 3041–3051, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. M. N. Saha, H. Jiang, Y. Yang et al., “Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma,” PLoS ONE, vol. 7, no. 1, Article ID e30215, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. R. J. Jones, C. C. Bjorklund, V. Baladandayuthapani, D. J. Kuhn, and R. Z. Orlowski, “Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA,” Molecular Cancer Therapeutics, vol. 11, no. 10, pp. 2243–2253, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Shangary and S. Wang, “Targeting the MDM2-p53 interaction for cancer therapy,” Clinical Cancer Research, vol. 14, no. 17, pp. 5318–5324, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. A. M. Sosin, A. M. Burger, A. Siddiqi, J. Abrams, R. M. Mohammad, and A. M. Al-Katib, “HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas,” Journal of Hematology and Oncology, vol. 5, article 57, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. R. M. Mohammad, J. Wu, A. S. Azmi et al., “An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals,” Molecular Cancer, vol. 8, article 115, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. J. M. R. Lambert, P. Gorzov, D. B. Veprintsev et al., “PRIMA-1 reactivates mutant p53 by covalent binding to the core domain,” Cancer Cell, vol. 15, no. 5, pp. 376–388, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Liang, C. Besch-Williford, and S. M. Hyder, “PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein,” International Journal of Oncology, vol. 35, no. 5, pp. 1015–1023, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. R. Zandi, G. Selivanova, C. L. Christensen, T. A. Gerds, B. M. Willumsen, and H. S. Poulsen, “PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53,” Clinical Cancer Research, vol. 17, no. 9, pp. 2830–2841, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. R. L. Messina, M. Sanfilippo, V. Vella et al., “Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells,” International Journal of Cancer, vol. 130, no. 10, pp. 2259–2270, 2012. View at Publisher · View at Google Scholar
  75. V. J. N. Bykov, N. Issaeva, A. Shilov et al., “Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound,” Nature Medicine, vol. 8, no. 3, pp. 282–288, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. N. Zache, J. M. R. Lambert, K. G. Wiman, and V. J. N. Bykov, “PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53,” Cellular Oncology, vol. 30, no. 5, pp. 411–418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. V. J. N. Bykov, N. Zache, H. Stridh et al., “PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis,” Oncogene, vol. 24, no. 21, pp. 3484–3491, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Nahi, S. Lehmann, L. Mollgard et al., “Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion,” British Journal of Haematology, vol. 127, no. 3, pp. 285–291, 2004. View at Publisher · View at Google Scholar · View at Scopus
  79. M. N. Saha, H. Jiang, Y. Yang, D. Reece, and H. Chang, “PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa,” Molecular Cancer Therapeutics, vol. 12, no. 11, pp. 2331–2341, 2013. View at Publisher · View at Google Scholar
  80. S. Lehmann, V. J. N. Bykov, D. Ali et al., “Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer,” Journal of Clinical Oncology, vol. 30, no. 29, pp. 3633–3639, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. H. Nahi, M. Merup, S. Lehmann et al., “PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion,” British Journal of Haematology, vol. 132, no. 2, pp. 230–236, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. J. M. R. Lambert, A. Moshfegh, P. Hainaut, K. G. Wiman, and V. J. N. Bykov, “Mutant p53 reactivation by PRIMA-1 MET induces multiple signaling pathways converging on apoptosis,” Oncogene, vol. 29, no. 9, pp. 1329–1338, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. V. J. N. Bykov, N. Issaeva, N. Zache et al., “Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs,” Journal of Biological Chemistry, vol. 280, no. 34, pp. 30384–30391, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. C. F. Cheok, C. S. Verma, J. Baselga, and D. P. Lane, “Translating p53 into the clinic,” Nature Reviews Clinical Oncology, vol. 8, no. 1, pp. 25–37, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Surget, D. Chiron, P. Gomez-Bougie et al., “Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells,” Cancer Research, vol. 72, no. 17, pp. 4562–4573, 2012. View at Publisher · View at Google Scholar · View at Scopus